

COMMON MINIMUM TECHNICAL STANDARDS AND PROTOCOLS FOR BIOBANKS DEDICATED TO CANCER RESEARCH

MAIMUNA MENDY, ELODIE CABOUX, RITA T. LAWLOR,
JESSICA WRIGHT, AND CHRISTOPHER P. WILD

IARC TECHNICAL
PUBLICATION NO. 44

COMMON MINIMUM TECHNICAL STANDARDS AND PROTOCOLS FOR BIOBANKS DEDICATED TO CANCER RESEARCH

MAIMUNA MENDY, ELODIE CABOUX, RITA T. LAWLOR,
JESSICA WRIGHT, AND CHRISTOPHER P. WILD

IARC TECHNICAL
PUBLICATION NO. 44

Published by the International Agency for Research on Cancer,
150 cours Albert Thomas, 69372 Lyon Cedex 08, France

©International Agency for Research on Cancer, 2017

Distributed by
WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland
(tel: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int).

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions
of Protocol 2 of the Universal Copyright Convention. All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of
any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status
of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or
recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The authors alone are responsible for the views expressed in this publication.

The International Agency for Research on Cancer welcomes requests for permission to reproduce or translate its
publications, in part or in full. Requests for permission to reproduce or translate IARC publications – whether for sale or
for non-commercial distribution – should be addressed to the IARC Communications Group, at: publications@iarc.fr.

Cover image: Paraffin-embedded tissues processed and stored within the context of various IARC research projects
(Credit: R. Dray/IARC).

This book is also available in electronic format from
<http://publications.iarc.fr>.

IARC Library Cataloguing in Publication Data

Common minimum technical standards and protocols for biobanks dedicated to cancer research / Maimuna Mendy,
Elodie Caboux, Rita T. Lawlor... [et al.]

(IARC Technical Publications; 44)

1. Biological Specimen Banks – Standards 2. Biological Specimen Banks – Organization & Administration
3. Biological Specimen Banks – Methods 4. Neoplasms

I. Mendy, M. II. Title III. Series

ISBN 978-92-832-2463-1
ISSN 1012-7348

(NLM Classification: W1)

Table of contents

Contributors	iv
Acknowledgements	v
Foreword	vi
Preamble	vii
Abbreviations	ix
 Section 1	 1
Glossary and definitions	
 Section 2	 5
Role of biobanks in cancer research	
 Section 3	 11
Recommendations for biobanks	
 Section 4	 55
Selected protocols	
 References	 63
 Annex 1	 69
IARC policy on access to human biological materials	
 Annex 2	 75
Guidelines for informed consent	
 Annex 3	 80
Template consent form for biobanking	
 Annex 4	 91
Template Material/Data Transfer Agreement (MTA/DTA)	
 Annex 5	 97
Biobank, collection, study, and sample minimum data set and associated standards	
 Disclosures of interests	 101

Contributors

Authors

Dr Maimuna Mendy

Head, Laboratory Services and
Biobank Group
International Agency for Research
on Cancer (IARC)
Lyon, France

Dr Elodie Caboux

Laboratory Services and
Biobank Group
International Agency for Research
on Cancer (IARC)
Lyon, France

Dr Rita T. Lawlor

ARC-NET Centre for Applied
Research on Cancer
University of Verona
Verona, Italy

Dr Jessica Wright

Study Manager, Sheffield Clinical
Trials Research Unit
The University of Sheffield
Sheffield, United Kingdom

Dr Christopher P. Wild

Director, International Agency for
Research on Cancer (IARC)
Lyon, France

Reviewers

The authors are grateful to the
following expert colleagues who
contributed comments, advice,
corrections, and protocols in the
preparation of this book.

Dr Joakim Dillner

Karolinska Institutet
Stockholm, Sweden

Ms Marianne Henderson

Senior Advisor for Division
Resources, Office of the Director,
Division of Cancer Epidemiology
and Genetics
Senior Advisor on Biobanking,
Center for Global Health, National
Cancer Institute, National Institutes
of Health, Division of Health and
Human Services
Rockville, MD, USA

Dr Jan-Eric Litton

Director General, Biobanking and
BioMolecular resources Research
Infrastructure—European Research
Infrastructure Consortium (BBMRI-
ERIC)
Graz, Austria

Dr Manuel Morente

Biobank Scientific Director, Spanish
National Cancer Research Centre
(CNIO)
Coordinator, Spanish National
Biobank Network
Past-President, European, Middle
Eastern and African Society for
Biopreservation and Biobanking
(ESBB)
Madrid, Spain

Dr Sabina Rinaldi

Biomarkers Group, Section of
Nutrition and Metabolism
International Agency for Research
on Cancer (IARC)
Lyon, France

Dr Ghislaine Scélo

Genetic Epidemiology Group,
Section of Genetics
International Agency for Research
on Cancer (IARC)
Lyon, France

Ms Anne-Marie Tassé

Executive Director,
Public Population Project in
Genomics and Society (P3G)
Montreal, Canada

Dr Jim Vaught

President, International Society
for Biological and Environmental
Repositories (ISBER)
Editor in Chief, *Biopreservation
and Biobanking*
Senior Research Fellow,
International Prevention Research
Institute, Lyon, France

Dr Kurt Zatloukal

Deputy Head, Institute of Pathology
Medical University of Graz
Graz, Austria

Mr Ma'n H. Zawati

Executive Director, Centre of
Genomics and Policy
McGill University
Montreal, Canada

Production Team

Karen Müller

English Editor

Sylvia Lesage

Publishing Assistant

Acknowledgements

We would like to acknowledge the authors of *Common Minimum Technical Standards and Protocols for Biological Resource Centres Dedicated to Cancer Research* (published by IARC in 2007): an IARC Secretariat composed of Dr Elodie Caboux, Dr Amelie Plymoth, and Dr Pierre Hainaut, joined by the Working Group participants.

The authors would like to thank Ms Sally Moldan, for her excellent contribution towards the compilation of this book, and the members and partners of the Low- and Middle-Income Countries (LMICs) Biobank and Cohort Building Network (BCNet), for sharing their real-life experiences working in resource-constrained settings.

Foreword

Biological specimens collected, processed, and stored under optimal conditions increasingly provide a necessary foundation for cancer research. Information obtained from such samples opens opportunities to learn more about the causes, prevention, and treatment of the disease. International comparisons made possible by the study of sample collections from different parts of the world are also invaluable in the pursuit of the evidence base for cancer control.

However, the above-mentioned opportunities are accompanied by many challenges and potential pitfalls. At times, pragmatic decisions have to be made in response to the constraints faced when conducting clinical or population-based studies. These constraints may be technical, may relate to infrastructure or finance, or may be ethical, legal, or social in nature. Being unaware of these types of risk to successful biobanking can place important scientific advances in jeopardy.

In this context, it is a great pleasure to introduce this publication

from the International Agency for Research on Cancer (IARC). The purpose of the text is to provide clear and practical advice on the common practices needed to create and maintain biobanks, recognizing that the circumstances faced by the curators of biobanks vary across the world. The international cooperation that went into formulating these Common Minimal Technical Standards provides confidence that the content is realistic, while at the same time maintaining the minimal standards needed in order for the biospecimens to be valid and to yield the reliable research data being sought. In providing this Foreword, I would like to place on record my thanks to all authors and reviewers who have contributed to this final product, as well as to all the contributors to *Common Minimum Technical Standards and Protocols for Biological Resource Centres Dedicated to Cancer Research*, known as the “Green Book”, published by IARC in 2007.

In publishing this book, my hope is for a balanced focus, not only on

what goes into a biobank but also on what comes out. There is a risk that biobanks remain untouched or underexploited, a deposit that is rarely put to work for the common good. While this book aims to ensure that what goes into a biobank is of high quality and well managed, it has as its ultimate objective to drive the use of those same biospecimens in research. This will involve the analysis of biospecimens, but to maximize the benefits it will also require linkage to other well-documented epidemiological and clinical data sets. In this period of spiralling numbers of cancer cases and costs of cancer care, the failure to use stored samples to answer critical research questions is indefensible.

In conclusion, I trust that readers will find this publication to be a support to successful biobanking and will find herein one important foundation for cancer research in the 21st century.

Dr Christopher P. Wild
Director, International Agency
for Research on Cancer

Preamble

The International Agency for Research on Cancer (IARC) published *Common Minimum Technical Standards and Protocols for Biological Resources Centres Dedicated to Cancer Research*, known as the “Green Book”, in 2007. The recommendations and protocols in that publication were largely based on guidelines, procedures, and documentation on biorepositories developed by several working groups, institutions, regulatory bodies, and organizations, including the World Health Organization.

However, biobanking has developed at a rapid pace over the years, driven mainly by the push for personalized medicine, the need for high-quality biological resources and associated data for scientific research, and technological advancement of analytical platforms for molecular and genetic research. These developments have enabled the collection and analysis of large numbers of biospecimens in combination with epidemiological and clinical data collected across populations and involving multiple biobanks.

In response to these developmental changes and to promote collaborative projects, a wide range of biobanking stakeholders are establishing approaches and mechanisms for the harmonization of resources, including data. These stakeholders include international organizations, societies, and institutions, such as the United States National Cancer Institute (NCI), the International Society for Biological and Environmental Repositories (ISBER), the European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB), and the Biobanking and BioMolecular resources Research Infrastructure–European Research Infrastructure Consortium (BBMRI-ERIC). Their activities include the improvement of biobanking protocols and standards to provide high-quality samples and to adequately address ethical, legal, and social issues (ELSI).

This IARC Technical Publication includes guidelines and recommendations for biobanks not only in high-income countries but also in low- and middle-income countries

(LMICs). The recommendations are based on validated and/or evidence-based guidelines, taking into account the current knowledge of biobanking practices and standards resulting from projects such as Standardisation and Improvement of Generic Pre-analytical Tools and Procedures for In Vitro Diagnostics (SPIDIA), BBMRI–Large Prospective Cohorts (BBMRI–LPC), and the International Genomics Consortium (IGC), as well as the European Committee for Standardization (CEN) Technical Specifications for molecular in vitro diagnostic examinations and International Organization for Standardization (ISO) norm 15189 (ISO, 2012). ISO 15189 is currently under revision (<https://www.iso.org/obp/ui/#iso:std:iso:15189:ed-3:v2:en>), and the working groups of the Technical Committee of ISO 276 (http://www.iso.org/iso/home/standards_development/list_of_iso_technical_committees/iso_technical_committee.htm?commid=4514241) are dealing with biobanking quality issues, including terminology, bioresearch, bioprocessing, pre-analytical methods, isolation of

analytes, and data processing and integration.

This book also includes sections on sample sharing, ELSI, and harmonization guidelines important to support collaborative research efforts that make use of biological materials. In particular, the section on open access deals with the principles of sharing and provides recommendations for biobanks in relation to sample and data sharing, which is key to establishing research collaboration. The section on governance provides guidelines on governance structures for biobanks for transparent and ef-

fective running of the facilities. Templates for informed consent and Material and Data Transfer Agreements are available in the Annexes section.

This new book also benefits from the experience and knowledge gained by IARC from coordinating the LMICs Biobank and Cohort Building Network (BCNet) and managing an international biobank, which contains diverse collections of specimens and data drawn from studies across the world, including the European Prospective Investigation into Cancer and Nutrition (EPIC) collection.

The guidelines and recommendations are applicable to biobanks operating in different geographical locations, and although the book's focus is on biobanks dedicated to cancer research, the principles and guidelines outlined here are also applicable to non-cancer biobanks.

Table 1 presents a list of the main sources of information used to develop the recommendations presented in this book. Whenever appropriate, the book indicates references and links to more extensive documentation and protocols.

Table 1. Guidelines, procedures, and documentation on biobanks

Title	Authors/origin
Tissue banking for biomedical research	National Cancer Centre Singapore
Biorepository protocols	Australasian Biospecimen Network (ABN)/Australia
Standardizing tissue collection and quality control procedures for a European virtual frozen tissue bank network	European Human Frozen Tumour Tissue Bank (TuBaFrost)
Human tissue and biological samples for use in research: operational and ethical guidelines	Medical Research Council (MRC)/United Kingdom
2012 Best practices for repositories: collection, storage, retrieval, and distribution of biological materials for research	International Society for Biological and Environmental Repositories (ISBER)/International
NCI best practices for biospecimen resources	National Cancer Institute (NCI)/USA
Guidance on regulations for the transport of infectious substances	World Health Organization (WHO)/International
United Nations recommendations on the transport of dangerous goods, model regulations, 19th revised edition	United Nations Economic Commission for Europe (UNECE)/International
Recommendation Rec(2006)4 of the Committee of Ministers to Member States on research on biological materials of human origin	Council of Europe Committee of Ministers
Collection, transport, preparation, and storage of specimens for molecular methods: approved guideline	Clinical and Laboratory Standards Institute (CLSI)/USA
The Human Proteome Organization	Human Proteome Organization (HUPO)
Case studies of existing human tissue repositories: "best practices" for a biospecimen resource for the genomic and proteomic era	RAND Corporation/USA
Biological resource centres: underpinning the future of life sciences and biotechnology	Organisation for Economic Co-operation and Development (OECD)/International
OECD best practice guidelines for biological resource centres	Organisation for Economic Co-operation and Development (OECD)/International
Standard operating procedure for the collection of fresh frozen tissue samples	European Organisation for Research and Treatment of Cancer (EORTC)

Abbreviations

ACD	acid citrate dextrose
BBMRI-ERIC	Biobanking and BioMolecular resources Research Infrastructure–European Research Infrastructure Consortium
BBMRI-LPC	BBMRI–Large Prospective Cohorts
BCNet	LMICs Biobank and Cohort Building Network
BRIF	Bioresource Research Impact Factor
BRISQ	Biospecimen Reporting for Improved Study Quality
CEN	European Committee for Standardization
CO ₂	carbon dioxide
CSF	cerebrospinal fluid
DBS	dried blood spot
DEPC	diethylpyrocarbonate
DIN	DNA integrity number
DMSO	dimethyl sulfoxide
DNA	deoxyribonucleic acid
DR	disaster recovery
dsDNA	double-stranded DNA
DTA	Data Transfer Agreement
EDTA	ethylenediaminetetraacetic acid
ELSI	ethical, legal, and social issues
EPIC	European Prospective Investigation into Cancer and Nutrition
ESBB	European, Middle Eastern and African Society for Biopreservation and Biobanking
EU	European Union
FBS	fetal bovine serum
FFPE	formalin-fixed, paraffin-embedded
GA4GH	Global Alliance for Genomics and Health
gDNA	genomic DNA
HBV	hepatitis B virus
HIV	human immunodeficiency virus
IARC	International Agency for Research on Cancer
IATA	International Air Transport Association
ICAO	International Civil Aviation Organization

ISBER	International Society for Biological and Environmental Repositories
ISO	International Organization for Standardization
IT	information technology
LIMS	laboratory information management system
LMICs	low- and middle-income countries
LN ₂	liquid nitrogen
MIABIS	Minimum Information about Biobank Data Sharing
miRNA	microRNA
MTA	Material Transfer Agreement
NCI	United States National Cancer Institute
NIH	United States National Institutes of Health
OCT	optimal cutting temperature
OECD	Organisation for Economic Co-operation and Development
P3G	Public Population Project in Genomics and Society
PCR	polymerase chain reaction
QA	quality assurance
QC	quality control
QMS	quality management system
qPCR	quantitative PCR
R&D	research and development
RIN	RNA integrity number
RNA	ribonucleic acid
rRNA	ribosomal RNA
RT-PCR	reverse transcription PCR
SOPs	standard operating procedures
SPREC	Sample PREanalytical Code
ssDNA	single-stranded DNA
TNM	tumour–node–metastasis
TuBaFrost	European Human Frozen Tumour Tissue Bank
UNECE	United Nations Economic Commission for Europe
UV	ultraviolet
WHO	World Health Organization

SECTION 1.

Glossary and definitions

Unless otherwise defined in another context in this book, important terms are defined below.

Some of the definitions are according to the 2012 International Society for Biological and Environmental Repositories (ISBER) guidelines (ISBER, 2012).

It should be noted that the International Organization for Standardization (ISO) standards that are currently under development and will be released within 2 years (ISO/TC 276 Biotechnology) will include a section on biobanking definitions.

Adverse event

Any event that caused harm or had the potential to cause harm to any biobank personnel or visitors, including but not limited to breach of security of the premises and its contents, or harm to biospecimens or data integrity or linkage.

Aliquot

Aliquoting is a process in which a specimen is divided into separate parts, which are typically stored as individual samples. The term “aliquot” may also be used as a noun to denote a single sample. It is advisable to store aliquots in separate containers, to minimize loss due to unexpected equipment failure.

Analyte

A substance or chemical constituent that is determined in an analytical procedure.

Annotation

Additional information associated with a particular point in a document or other piece of information.

Anomaly

An unexpected event occurring within the quality management system,

usually detected by staff of the area in which the event occurred, which may result in non-compliance with the quality management system or with the requirements of the user.

Anonymization

The process in which identifying information or details are removed from the data collected with a sample, so that the sample donor remains anonymous.

Associated data

The clinical, pathological, and epidemiological information related to patients who provided a sample. The information relates to characteristics of the sample, the study participant, and biological experiments that can be used to generate knowledge.

Autopsy

The postmortem examination of

organs and tissues of a body, to determine cause of death or pathological conditions.

Biobank

Infrastructure for the collection, archiving, and storage of biospecimens and their associated data, and the procedures and related services connected to the biospecimens and associated data. The services include informing individuals who are approached to participate in a study, obtaining their consent, collecting and processing specimens for secure long-term storage, accessing and retrieving specimens appropriate for analysis, processing for preparation of biomaterials (e.g. DNA, RNA, proteins), quality control, and packaging and shipping of specimens. Many types of biobank are relevant to cancer research. They include, among others, tumour and tissue biobanks for specimens and data obtained in the course of normal clinical procedures; specialized collections of specimens and data developed in the context of clinical trials, mechanistic studies, or diagnostic or prognostic studies; and collections of specimens and data developed in epidemiological studies and biomarker studies. Biobank samples include tissues, blood, cell lines, DNA, and proteins derived from individuals with a history of hereditary or familial cancer. Biobanks are also known as biorepositories.

Biobanking

The process of storing material or specimens and associated data for future use.

Biohazard

An organism, or a substance derived from an organism, that poses a threat to (primarily) human health. This can include medical waste and samples of a microorganism, virus, or toxin (from a biological source)

that can affect human health. It can also include substances harmful to animals.

Biological resource

A collection of biological specimens and associated data that are acquired for a defined purpose. The custodian of the collection is responsible for the management of the biological resource. Biological resources may be stored in a biobank or laboratory and in databases, depending on the number of samples, the volume of information, and the governance structure of the biobank.

Biological safety hood

A cabinet designed to provide a microbe-free work environment, which enables work on samples in an isolated area.

Biorepository

See “Biobank”.

Coding

Substituting a code for personally identifying information in such a way that linkage is only possible through a key.

Cold chain

A temperature-controlled supply chain.

Cold ischaemia

The condition of a tissue sample after its removal from the body until its stabilization or fixation.

Collection

The practice or technique of collecting a specimen, or a specific sample or group of samples, that has been isolated for future research purposes.

Consignee

Any individual, agency, institution, or organization that receives specimens and assumes responsibility for storing, dispensing, and tracking the disposition of specimens.

Container

An enclosure for one or more units of a specimen or specimens.

Controlled areas

Restricted work areas of low microbial and particulate content in which non-sterile materials are prepared.

Custodian

The person responsible for the management of a biological resource. The custodian works with other key stakeholders in the management of the resource, including the tracking of all relevant documentation for the resource, and is responsible for ensuring that policies on access to the resource are in place and are implemented according to appropriate guidelines.

Database

A structured collection of records or data that is stored in a computer system so that a computer program or a person using a query language can consult it to answer queries.

Dehydration

The removal of water from a tissue.

De-identification

A process that ensures that a person's identity cannot be connected with information or samples donated by them.

Desiccant

A desiccant is a hygroscopic substance that induces or sustains a state of dryness (desiccation) in its vicinity. Commonly encountered pre-packaged desiccants are solids that absorb water.

Deviation

An intentional or unintentional event that departs from a set procedure or normal practice.

Dewar

A specialized container that holds

liquefied gases. A dewar may also be referred to as a dewar flask or dewar vessel, or a liquid nitrogen tank.

Distribution

A process that includes receipt of a request for specimens, selection of appropriate specimens, and final inspection, in conjunction with subsequent shipment and delivery of specimens to another biobank, specimen collection centre, or laboratory.

Donor

A person who donates or gives an organ, blood, or blood products to another person.

Dry ice

Solid-phase carbon dioxide (CO₂). CO₂ solidifies at -78.5 °C.

End user

A health-care practitioner, scientist, or laboratory staff member who performs an appropriate procedure, test, or archival function.

Error

A deviation from a standard operating procedure (SOP) during specimen retrieval, processing, testing, quarantining, labelling, storage, or distribution that might adversely affect the specimen.

Ethical, legal, and social issues (ELSI)

The ethical, legal, and social issues associated with the development and operation of a biobank.

Identifier

Information (e.g. name, social security number, medical record number, or pathology accession number) that would enable the identification of the subject. For some specimens, this information might include the taxon name and the collection number.

Incident

Any unplanned occurrence that deviates from standard operating procedures (SOPs) or applicable government laws and regulations during specimen retrieval, processing, labelling, storage, or distribution that may affect subsequent use of those specimens.

Individual

The person who is the subject of protected health information.

Informed consent

A decision to participate in research, taken by a competent individual who has received the necessary information; who has adequately understood the information; and who, after considering the information, has arrived at a decision without having been subjected to coercion, undue influence, inducement, or intimidation.

Institution

The body responsible for specimen collection and archiving that commits itself to the development, management, and long-term maintenance of a biobank. Although the organizational nature of such institutions may vary widely, they are primarily clinical cancer centres, academic medical centres, research institutes closely associated with clinical centres, or central organizations dedicated to the management of biobanks.

Institutional review board (IRB)

See “Research ethics committee (REC)”.

Label

Any written, printed, or graphic material on or affixed to a specimen container or package.

Liquid nitrogen (LN₂)

Coolant used to cool and store samples. Nitrogen becomes liquid

at -196 °C. Samples stored in the vapour phase of liquid nitrogen are -190 °C and warmer, depending on the distance from the liquid phase.

Liquid nitrogen tank

See “Dewar”.

Lyophilized

Dehydrated for storage by conversion of the water content of a frozen specimen to a gaseous state under vacuum. Also called “freeze-dried”.

Material Transfer Agreement (MTA)/ Data Transfer Agreement (DTA)

An agreement or contract that governs the transfer of research materials and/or data between two organizations, when the recipient intends to use them for research purposes. It defines the rights and obligations of the provider and the recipient with respect to the use of the materials and/or data.

Monitoring system

A system that monitors the temperature and environmental conditions, including alarms, in conjunction with remote access, security features, and electronic data storage.

Participant

A person who takes part in a trial. Participants must usually meet certain eligibility criteria.

Patient

A person who receives medical attention, care, or treatment.

Pre-analytical data

Factors that may have an impact on the integrity of the sample during the collection, processing, and storage processes. These data include information on the treatment of the sample, including the conditions and the duration of the treatment.

Preservation

The use of chemical agents, alterations

in environmental conditions, or other means during processing and storage to prevent or retard biological or physical deterioration of a specimen.

Procedure

A series of steps that, when followed in order, are designed to result in a specific outcome.

Processing

Any procedure used after specimen collection but before distribution, including preparation, testing, and releasing the specimen to inventory and labelling.

Pseudo-anonymization

The process whereby identifiable personal information is anonymized, but in such a way that the personal identifiers are replaced by one pseudonym, which can be linked across multiple data records without revealing the identity of the person.

Quality

Conformance of a specimen or process with pre-established specifications or standards.

Quality assurance (QA)

An integrated system of management activities involving planning, implementation, documentation, assessment, and improvement to ensure that a process or item is of the type and quality needed for the project.

Quality control (QC)

The system of technical activities that measures the attributes and performances of a process or item against defined standards, to verify that the stated requirements are fully met.

Quality management system (QMS)

The organizational structure, procedures, processes, and resources needed to implement quality management.

Re-identification

A reversible process that allows data from which identifiers have been removed, and replaced by a code, to be re-identified and linked to a specific individual by, for example, using the code or linking different data sets.

Removal

See "Retrieval".

Repository

An entity that receives, stores, processes, and/or disseminates specimens, as needed. This term encompasses the physical location as well as the full range of activities associated with its operation. A repository may also be referred to as a biorepository or a biobank.

Research ethics committee (REC)

A board, committee, or other group formally designated by an institution to review the ethical, legal, social, scientific, and financial implications of biomedical research involving humans as subjects, to approve the initiation of the research, and to conduct periodic reviews of such research. In some countries, this body is known as an institutional review board (IRB) or a research ethics board (REB).

Retrieval

The removal, acquisition, recovery, harvesting, or collection of specimens.

Safety

Processes, procedures, and technologies to ensure freedom from danger or harm.

Sample

A single unit containing material derived from one specimen.

Shipping manifest

A written description of the contents of a shipped package.

Snap-freezing

The process by which the temperature of samples is lowered very rapidly to below -70°C using dry ice or liquid nitrogen.

Specimen

A specific tissue sample, blood sample, and so on taken from a single subject or donor at a specific time.

Standard operating procedures (SOPs)

A set of detailed written instructions to achieve uniformity of the performance of a specific function.

Storage

Maintenance of specimens under specified conditions for future use.

Subject

A living or deceased individual who is the source of the specimen in accordance with established medical criteria, procedures, and privacy regulations. In some countries, the term "Donor" or "Individual" may be used in the same context as "Subject", especially in the context of human specimens.

Traceability

The ability to locate a specimen during any step of its donation, collection, processing, testing, storage, and disposition.

Warm ischaemia

The condition in which the tissue is deprived of its normal blood supply, containing oxygen and nutrients, while the tissue is at body temperature.

Selected protocols

4.1 Processing of blood specimens

If serum and plasma samples are being collected, the blood should be centrifuged as soon as possible after blood collection and separated immediately after centrifuging so that the samples can be frozen as soon as possible. This is critical for time-sensitive samples for protein studies, for example. For the processing of blood specimens, the following protocols are recommended.

4.1.1 Filter paper dried blood spot collection, processing, storage, and shipment

Dried blood spot (DBS) is an easy and inexpensive means of collection and storage of peripheral blood specimens in settings where collection and storage of plasma is not optimal.

DBS can be used for molecular biology techniques and other diagnostic assays. The cost and difficulty of cold chain shipping of plasma samples are greatly reduced by the use of DBS, which can be shipped as non-dangerous goods.

Always wear gloves when handling filter papers, and hold them only by the upper corner, marked out for labelling. Do not allow the card to come into contact with any unclean surface (e.g. bench, base of hood).

The procedure should be performed in accordance with the relevant health and safety practices specific to specimen handling and waste disposal. A minimum level of training is required to perform the procedure.

Reagents and materials required:

- finger prick device (e.g. Unistik 2 device; Fisher Scientific, 22-0227);
- alcohol swab;

- Whatman Protein Saver Card (e.g. Whatman, 903; 10534612);
- gas-impermeable storage bag (e.g. Fisher Scientific, NC9307519);
- desiccant pack (e.g. Whatman, 10548234);
- humidity indicator cards (e.g. Multi-sorb Des Manufacture, MS200032);
- card drying rack (e.g. VWR, 89015-592) (optional; cards can be placed on a dry worktop if a drying rack is not available);
- gloves, preferably powder-free; and
- sample label.

4.1.1.1 Collection of DBS from finger prick

- Disinfect the selected site and prick it using a lancet/needle.
- Uniformly saturate the entire circle by quickly and gently touching, not pressing, the puncture site to the filter paper.

- iii. Note: Do not touch the Whatman card at any stage of collection.
- iv. After the collection of five blood spots, clean the site and leave it unbandaged.
- v. Allow the blood spots to air-dry, without the flap covering the spots, in a clean dry place that is protected from rodents or insects and direct sunlight, for at least 4 hours (overnight drying may be needed in areas with higher humidity).
- vi. Do not heat or stack DBS cards or allow them to touch other surfaces during the drying process.
- vii. Tuck in the flap of the card as indicated on the card.
- viii. Clearly label the card with the patient identifier and date, or label it with a prepared barcode label.
- ix. Be sure the DBS card is completely dry before packing.
- x. Insert the DBS card into a gas-impermeable plastic bag containing a desiccant pack and a humidity indicator. Do not store more than one card per bag.
- xi. Ensure that the patient identifier and date (or the prepared barcode label) are on the outside of the bag as well as on the DBS card.
- xii. Seal the plastic bag.
- xiii. Place the sealed bag containing the DBS card in a clean, dry area of the laboratory with no exposure to direct sunlight, free of insects or rodents, and where ambient temperatures will not exceed 30 °C.
- xiv. The room should be temperature- and humidity-controlled (temperature of 20–22 °C and humidity of not more than 22%).
- xv. Check the desiccant pack before shipment of the DBS card and replace it if the colour of the humidity indicator has changed from blue to pink or colourless.
- xvi. Ship the DBS cards at ambient temperature.

4.1.1.2 Preparation of DBS from EDTA, ACD, or heparin tubes

DBS can also be prepared from EDTA, ACD, and heparin blood tubes.

- i. Before starting, mix vacutainers containing anticoagulated blood by inversion.
- ii. Wipe the top of the vacutainer with 70% ethanol before opening the lid.
- iii. Using a micropipette, apply 40 µL of blood onto the circle on the DBS card.
- iv. Air-dry the filter paper thoroughly by following step v above (Section 4.1.1.1), and continue with the rest of the protocol as described above.

4.1.1.3 Shipping of DBS cards

DBS are classified as “Exempt Biological Specimens” according to the ICAO and IATA shipping regulations. DBS bags should be shipped in courier envelopes or boxes under ambient conditions according to the triple packaging system (see Section 3.9.2).

- i. Provide a shipping manifest for all boxes. The shipping manifests must exactly match the label information and the order in the associated shipment, including the global specimen IDs.
- ii. Provide a box map for all boxes. The box maps must exactly match the label information and the order in the associated shipment, including the global specimen IDs.
- iii. Record the courier service and the courier air bill number on the specimen shipment notice.
- iv. Advance notification of shipment must be made to the recipient.

4.1.2 Whole blood

Whole blood is to be prepared from EDTA tubes. The anticoagulated blood can be snap-frozen as it is. If the blood cells are needed intact,

DMSO is needed to keep them alive while freezing.

- i. Dispense 50 µL of DMSO into two 1 mL sterile cryovials.
- ii. Invert the EDTA tube twice, and then add 450 µL of blood to each cryovial.
- iii. Invert the cryovial to mix the whole blood with the DMSO. Note: DMSO is cytotoxic at room temperature; therefore, as soon as it is mixed with blood, it should be placed in a controlled-rate freezer.
- iv. Transfer to –80 °C after at least 4 hours.

4.1.3 Plasma

Plasma collected in EDTA or ACD tubes can be used for bioassays, plasma DNA isolation, proteomic analysis, and biomarker discovery.

- i. Spin the vacutainer (about 9 mL) at 815g for 10 minutes at 4 °C to separate plasma from blood cells.
- ii. After wiping each tube with 70% alcohol, remove about 3 mL of plasma. (The tube can be retained for white blood cell extraction.)
- iii. Transfer to a labelled 15 mL tube, and centrifuge at 2500g for 10 minutes at 4 °C.
- iv. Aliquot plasma into 1 mL labelled cryovials (three or four aliquots).
- v. Place in LN₂ dewar to snap-freeze.
- vi. Store at –80 °C or in LN₂.

The purpose of double-spinning the plasma is to remove all cellular contaminants so that the plasma is suitable for plasma DNA analysis. Therefore, it is extremely important not to disturb the buffy coat after the first spin and any pellet after the second spin.

4.1.4 Platelet-poor plasma

Platelet-poor plasma can be used for the isolation of plasma DNA (from EDTA tubes).

- i. Spin blood at 3200g for 12 minutes at room temperature.
- ii. Pipette off plasma using a plastic Pasteur pipette. Transfer into a tube.
- iii. Spin plasma at 2000g for 10 minutes at 4 °C.
- iv. Aliquot into 1 mL aliquots in labelled cryovials.
- v. Store at -80 °C.
- v. If division of the sample is necessary, at this point pour 25 mL of the sample into another centrifuge tube.
- vi. Spin both tubes at 1200g for 10 minutes.
- vii. Repeat the washing if red blood cells persist.
- viii. Carefully pour off the supernatant.
- ix. Using a swirling motion, remove the pellet with a pipette and transfer it to a labelled cryovial.
- x. Store at -80 °C or in LN₂ until further use.
- vii. Spin at 450g for 10 minutes.
- viii. Pour off the supernatant into a waste container containing chlorine bleach. Add 3 mL of cold freezing mix (10% DMSO, 20% fetal calf serum [FCS], RPMI 1640) and resuspend.
- ix. Dispense the white blood cells into three 1 mL labelled cryovials that have been sitting on ice.
- x. Place on ice. Place vials in a controlled-rate freezer so as to cryopreserve cells under conditions that maintain cell viability. This should be done as soon as possible, because DMSO is toxic at room temperature.
- xi. Transfer on a weekly basis to LN₂ tanks.

As an alternative, red blood cells can be lysed by using an ammonium-containing lysis buffer.

4.1.5 Buffy coat cells

The buffy coat is a thin, greyish-white layer of white blood cells (leukocytes and lymphocytes) and platelets covering the top of the packed red blood cells after centrifugation at 450g (from EDTA- or ACD-containing blood tubes).

- i. After having spun the blood, take the buffy coat off with about 100 µL of plasma using a disposable sterile Pasteur pipette; be careful not to lift red blood cells.
- ii. Lyse the remaining red blood cells by addition of red blood cell lysis buffer at room temperature.
- iii. Spin the tube at 450g for 10 minutes at room temperature.
- iv. Resuspend the pellet.
- v. Aliquot as appropriate into labelled cryovials.
- vi. Place in LN₂ to snap-freeze.
- vii. Store in LN₂.

4.1.6 Blood pellets (white blood cells)

Blood pellets can be used for the isolation of DNA (from EDTA or ACD tubes).

- i. Transfer blood from the original tube to a labelled 50 mL tube.
- ii. Fill the tube with Tris-EDTA buffer (formula) and mix vigorously. Place on ice for 5–10 minutes.
- iii. Spin at 1200g for 10 minutes.
- iv. Carefully pour off the supernatant into a waste container containing chlorine bleach. Briefly vortex the pellet and add 50 mL of Tris-EDTA buffer. Shake vigorously.

4.1.7 White blood cells

White blood cells collected in EDTA or ACD tubes can be used for DNA extraction and the creation of cell lines.

- i. Transfer the remaining blood from the plasma spin to a labelled 50 mL tube containing 10 mL of RPMI 1640.
- ii. After swabbing the lid of this tube with alcohol, aliquot 3 mL of Ficoll into each of two clearly labelled 15 mL tubes.
- iii. Carefully layer 9 mL of diluted blood onto each tube of Ficoll. Treat gently, and do not mix, but spin as soon as possible.
- iv. Spin at 450g for 30 minutes. Note: When centrifuging, do not use the brake.
- v. Remove most of the top layer (RPMI 1640) using a 1 mL Eppendorf tip, and discard about 3–4 mL into a waste container containing chlorine bleach.
- vi. Collect white blood cells with the same Eppendorf tip using a swirling motion to “vacuum up” white blood cells. Do not take too much Ficoll (third layer), because it is toxic to the cells. Place the white blood cells into a labelled 15 mL tube containing 10 mL of RPMI 1640.

Instead of a separation based on Ficoll, a Percoll separation can be used.

4.1.8 Serum

The blood is collected into tubes without addition of anticoagulants. Then, two phases are distinguishable: a solid phase containing fibrin and cells, and a fluid phase containing the serum.

This process should be completed after 30 minutes at room temperature, after which the process described below should start.

- i. Spin blood at 1500g for 10 minutes at room temperature.
- ii. Aliquot 1 mL portions of the supernatant into labelled cryovials.
- iii. Place into LN₂ dewar or dry ice to snap-freeze.
- iv. Transfer to -80 °C freezer or LN₂.

4.2 Processing of solid tissue

Careful and well-documented processing of tissue specimens is crucial to the overall usefulness of the biobank as a resource for scientific research. Detailed records of the first steps in the process of sample handling include the times of anaesthesia administration, ligation of

vessels, and specimen removal from the patient.

These factors are important to assess tissue quality, because they affect the quality of the resulting biomolecules. The most commonly described factor that has an impact on tissue quality is the warm ischaemia time, which is the period from when the blood supply is ligated until the specimen is placed in fixative in the pathology laboratory. Studies have demonstrated that changes in both RNA and protein occur during this time (Dash et al., 2002).

These protocols for collecting and freezing tissue samples were developed within the European Human Frozen Tumour Tissue Bank (TuBaFrost) project (Riegman et al., 2006b) and the Standardisation and Improvement of Generic Pre-analytical Tools and Procedures for In Vitro Diagnostics (SPIDIA) project (Malentacchi et al., 2015).

These recommended protocols contain choices and recommendations for preserving solid tissue, and describe the roles of key people involved in the process. Consult the CEN norms for more detailed information on the processing of snap-frozen tissue and FFPE samples for protein DNA and RNA isolation (CEN/TS 16826-1–2 and CEN/TS 16827-1–3).

4.2.1 Snap-freezing

Snap-freezing is the process by which samples are lowered to temperatures below -70°C very rapidly using dry ice or LN_2 . This method can provide excellent sample integrity and a wide array of options for tissue analysis, including extraction of proteins, RNA, and DNA for use in research diagnosis. Before tissues are stabilized by freezing, the protein, RNA, and DNA profiles can change, and these changes depend on the duration of warm and cold ischaemia and the ambient temperature before

freezing. All the different pre-analytical conditions and durations should be documented.

4.2.1.1 Safety

All procedures should be carried out in accordance with the local codes of practice. Working with LN_2 and isopentane is hazardous; all procedures must comply with local safety rules specific to these chemicals. All tissue must be handled as if it is potentially infectious.

4.2.1.2 Hospital ward

Consent must be obtained from the patient before surgery (if applicable, according to the law and procedures in the country where the samples are being collected).

4.2.1.3 Operating theatre

- i. Deliver the notification of tissue collection (and the consent form, if needed) to the surgeon, or highlight on the operating list.
- ii. The surgeon should:
 - a. complete the pathology form (if possible, in advance);
 - b. perform the operative procedure and record the time of arterial clamping and of excision of the specimen; and
 - c. place the specimen in a labelled sterile pot or bag and put it on ice.
- iii. The operating theatre staff should send the fresh tissue specimen to the pathology department immediately.

4.2.1.4 Histopathology department

- i. Notify the pathologist and the tissue bank research technician (if not already present).
- ii. Check the paperwork and allocate a pathology number to the specimen as routine.

4.2.1.5 Role of the pathologist

- i. Macroscopically describe the specimen as usual.
- ii. Using clean instruments and on a clean surface (sterile foil or clean dissection board), dissect the tissue specimen. Clean or change instruments between dissecting normal tissue and tumour tissue.
- iii. Take representative parts of tissue for routine diagnosis (for fixation and embedding) as a priority, and decide whether there is sufficient material available for the tissue bank.
 - a. Supply the research technician with a tissue sample or samples for biobanking representative parts of the lesion, normal tissue, and pre-malignant conditions.
 - b. Perform QC of frozen tissue and annotation.

4.2.1.6 Role of the technician

- i. Prepare the tissue sample for snap-freezing on a clean surface and using clean instruments; change instruments between preparing normal tissue and tumour tissue. The minimum volume of tissue for snap-freezing is approximately 0.5 cm^3 , although the amount of tissue available will differ depending on the sample site. Smaller fragments should still be snap-frozen and stored in the tissue bank; if there is sufficient material, freeze duplicate samples.
- ii. Pre-cool the freezing medium isopentane (2-methylbutane) until opaque drops begin to appear in the isopentane and the solution becomes misty; this will bring the isopentane towards its freezing point (-160°C), the optimal freezing point for the tissue. Options:
 - a. LN_2 : suspend a vessel of isopentane in LN_2 .
 - b. Dry ice: add dry ice (cardice) to the isopentane until a slush is

- formed, or suspend a vessel of isopentane in dry ice.
- iii. Label cryovials, cryomoulds, or cryostraws with a barcode and/or sequential code (depending on local laboratory practice). Use a waterproof pen with ink that is able to withstand long-term storage at low temperatures. The sequential code is the local inventory code and must not relate to the pathology number or other identifiers. If a barcode is used, readable recognition must also be included to make the sample identifier readable at institutions where there are no barcode readers.
 - iv. Record the local sequential code, the pathology number, the date, the lag time from arterial clamping and excision to freezing, and the type of tissue (the site, and also whether the sample is tumour, normal, and/or pre-malignant) in the inventory book. If a barcode system is in use, the barcode can be scanned into the LIMS and the above-mentioned data recorded.
 - v. Freeze directly in isopentane. Do not remove the tissue from the isopentane until freezing is complete (5 seconds or less, depending on size), but ensure that the sample does not crack. Remove the sample from the isopentane and enclose it in the labelled cryovial. It is good practice to strive to snap-freeze all tissue within 30 minutes of excision from the patient. Tissue subject to a delay of up to 2 hours should still be collected and the delay noted within the local inventory database. Options for freezing:
 - a. Embed the tissue samples in OCT compound and freeze in isopentane, or freeze directly in isopentane. The isopentane used is cooled either by suspension in LN₂ or through addition of dry ice.

- b. Orientate the tissue on a piece of cork and an equally sized piece of Whatman paper soaked in physiological salt solution.
- c. If the cryostraw system is used to introduce a carrot of tissue into the straw, thermally seal each extremity and place in LN₂.

4.2.2 Storage of tissue

Storage of tissue can be done according to different protocols according to the equipment available in the facility. Options for storage:

- i. Transfer the snap-frozen sample from the isopentane to a pre-chilled storage container for transfer to either a locked -80 °C freezer or a LN₂ storage facility in the liquid or vapour phase. For storage for longer than 5 years, LN₂ in the liquid or vapour phase is recommended.
- ii. Place cryostraws in a designated visotube within a goblet (removable LN₂ storage elements) and place in the locked LN₂ repository.
 - a. Store duplicate samples in a different storage facility if this is available.
 - b. Check the backup system for the storage repository – either a backup freezer running constantly or adequate supplies of LN₂.
 - c. Record the storage details in the inventory system, and check earlier data that were entered. At a minimum, the information recorded will include the inventory number (local sequential code), the location, the pathology number, the type of tissue (the site, and also whether the sample is tumour, unaffected/normal, and/or pre-malignant), the lag time between excision and freezing, and the date.

4.2.3 Storage of FFPE blocks and slides

- i. FFPE blocks and sections mounted on slides can be stored at room temperature. Prevent exposure of blocks to sun or extreme temperature variation or humidity.
- ii. Store blocks in moisture-resistant cardboard boxes or plastic storage boxes.
- iii. Transfer details to the computerized database system.
- iv. Update the database when samples are moved or depleted.

4.2.4 Formalin fixation

Formalin fixation is standard practice in most routine histopathology laboratories. The following guidelines address specific issues related to preservation of formalin-fixed specimens in biobanks. Table 6 provides information on the composition of neutral buffered formalin.

- i. Tissue specimens should not be bigger than 3 cm × 2 cm × 0.5 cm.
- ii. Specimens should be fixed in fresh 10% neutral buffered formalin for a minimum of 4 hours and a maximum of 48 hours, after which they should be embedded in paraffin in accordance with conventional techniques.
- iii. All reagents should be DNase- and RNase-free (e.g. prepared using diethylpyrocarbonate [DEPC] water).
- iv. Fixation media, such as Bouin's solution, that contain picric acid should be avoided, because this compound interferes with subsequent PCR analysis of extracted nucleic acids.
- v. Alcohol fixation may be used as an alternative to formalin fixation. For this, tissue is placed into 70% alcohol (diluted with DEPC water) for a minimum of 4 hours. Because of the chemical hazards of formalin, it can be desirable to use alternatives to formalin as a routine

Table 6. Composition of neutral buffered formalin and 70% ethanol

Composition		Total volume
<i>10% neutral buffered formalin (in 40% formaldehyde)</i>		100 mL
100% formaldehyde	37–40 mL	
Na ₂ HPO ₄ (anhydrous)	6.5 g	
NaH ₂ PO ₄	4.0 g	
Distilled water	900 mL	
<i>70% ethanol</i>		
100% absolute alcohol	70 mL of absolute alcohol + 30 mL of water	100 mL
96% ethanol	73 mL of 96% ethanol + 27 mL of water	100 mL

fixative. However, the effect of long-term storage with these alternative fixatives on the desired macromolecules is not always known and should be established empirically.

4.2.5 RNAlater

This substance protects RNA in fresh specimens. It eliminates the need to immediately process or freeze samples.

4.2.5.1 Tissue

Cut the tissue to be smaller than 0.5 cm in at least one dimension, and then submerge the tissue in 5 volumes of RNAlater (e.g. a 0.5 g sample requires about 2.5 mL of RNAlater).

4.2.5.2 Cells

Resuspend the pelleted cells in a small volume of phosphate-buffered saline (PBS) before adding 5–10 volumes of RNAlater.

4.2.5.3 Storage

RNAlater-treated tissue and cell samples can be stored at 4 °C for 1 month, at 25 °C for 1 week, or at –20 °C for an indefinite period. For RNA isola-

tion, simply remove the tissue from RNAlater and process.

4.2.6 Shipment of tissues and slides

FFPE tissues and slides are shipped at ambient temperature in accordance with the established shipment guidelines and protocols of the sending and recipient institutions. Please refer to Section 3.9 for more details.

4.2.7 Quality control for tissue samples

- Ensure that the reagents have not expired and are of the correct composition and volumes.
- Keep high-quality records on all variables related to specimens, FFPE tissues, and slides, including the time of tissue collection, the processing time, and the period of storage before shipment and/or use.

4.2.8 Data to be recorded

- Date and time of tissue collection.
- Number of unprocessed samples, FFPE blocks, and slides prepared.
- Date and time of shipping.
- Any variations or deviations from the

protocol, problems, or issues related to the collection and storage.

4.3 Processing of urine and buccal cells

The following protocols for processing of urine and buccal cells contain recommended procedures.

4.3.1 Urine

- Plastic or glass containers for collection of urine should be clean and dry, should have a 50–3000 mL capacity, a wide mouth, and a leakproof cap, and should be clearly labelled.
- When in transit, urine collections should be maintained on ice or refrigerated.
- Urine should be aliquoted according to the volume needed for analysis or storage.
- Depending on the analyte to be measured, a preservative may be added during collection or before aliquoting.
- Store urine at –80 °C or below in LN₂.

4.3.2 Buccal cells

- A collection kit (containing mouthwash, a 50 mL plastic tube, a

plastic biohazard bottle, and courier packaging) is mailed or given to the participant, along with an instruction sheet. The participant is to brush their teeth as usual, rinse their mouth out well with water twice, and then wait 2 hours. The participant should not eat or drink anything other than water during this time.

- ii. After 2 hours, 10 mL of commercial mouthwash should be poured into the tube, and then 10 mL of tap water should be added. This diluted mouthwash should be placed into the mouth (without swallowing) and swished around vigorously for 30 seconds.
- iii. The mouthwash should then be spat back into the plastic tube, and the tube should be sealed tightly.
- iv. The sample should be sent back to the biobank immediately for processing, or stored at 4 °C until it is sent, but it should be sent within 24 hours.
- v. When the sample arrives at the laboratory, transfer the mouthwash to 15 mL conical test tubes.
- vi. Add 35 mL of Tris-EDTA to the mouthwash sample and spin at 450g for 5 minutes.
- vii. Decant the supernatant and discard.
- viii. Wash the cells twice, each time with 45 mL of Tris-EDTA.
- ix. Resuspend the cell pellet in 50 µL of Tris-EDTA and transfer to 2 mL labelled cryovials.
- x. Store the sample at -80 °C or in LN₂.

Note: Buccal cells can also be collected with other means, such as brushes.

4.4 Collection and processing of saliva

A research consortium at the University of California, Los Angeles was funded by the United States National Institute of Dental and Craniofacial Research to investigate the human

saliva proteome. The protocol for collection and processing of saliva is derived from the consortium's *Salivary Proteome Handbook Procedures and Protocols* (Hu et al., 2007).

- i. Saliva collection should be done in the morning (aim for 10:00–11:00 am if possible). Ask the subject to refrain from eating, drinking, or oral hygiene procedures for at least 1 hour before the collection.
- ii. The subject should be given drinking water (bottled) and asked to rinse their mouth out well (without drinking the water).
- iii. Five minutes after this oral rinse, the subject should be asked to spit whole saliva into a 50 mL sterile centrifuge tube. The subject should refrain from talking. It is better for the subject to drop their head down and let the saliva run naturally to the front of the mouth, hold this position for a while, and spit into the tube provided. The subject will spit into the collection tube about once a minute for up to 10 minutes. The goal for each whole saliva donation should be about 5 mL. Require that the tube be placed on ice while collecting whole saliva. Remind the subject not to cough up mucus, so that saliva is collected, not phlegm.
- iv. For the collection of submandibular saliva, use 2 × 2-inch cotton gauze to block the opening of each parotid duct. Dry up the floor of the mouth, and block the openings of the sublingual gland (both sides), and have the subject raise their tongue slightly to elevate the opening to the submandibular gland. Begin to collect submandibular saliva by using a sterilized Wolf device. A sterilized and disposable yellow tip (for pipette P200) should be connected into the device and changed after every collection. During the collection, at 2-minute intervals, a few grains of citric acid powder

should be swabbed with a moistened cotton applicator onto the lateral dorsum of the tongue to stimulate the secretion. Aim to collect at least 200 µL of submandibular saliva.

- v. For the collection of sublingual saliva, the protocol is similar to that described above for collection of submandibular saliva. The only difference is that the ductal orifices of the submandibular gland are blocked off. Aim to collect > 100 µL of sublingual saliva every time.
- vi. For the collection of parotid saliva, use a parotid cup to collect the saliva. Parotid cups may be placed bilaterally if the clinical investigator so chooses. This will enable the simultaneous collection from each parotid gland. The citric acid stimulation should be performed as described above. Aim to collect > 1 mL of parotid saliva. The first 0.1 mL of parotid saliva collected should be discarded, to ensure that fresh parotid saliva is obtained.
Note: The collected samples should be kept on ice at all times before processing.
- vii. For sample processing using proteinase inhibitors, to each 100 µL of saliva:
 - a. Add 0.2 µL of proteinase inhibitor cocktail from standard stock solution (Sigma, P8340), and invert gently.
 - b. Add 0.3 µL of sodium orthovanadate (Na₃VO₄) (Sigma, S6508) from standard stock of 400 mM, and invert gently.
- viii. Centrifuge the specimens at 2600g for 15 minutes at 4 °C (if you note that incomplete separation has occurred, increase the spin time to 20 minutes). Then:
 - a. Remove the supernatants from the samples and label them with the term “super”, which stands for the supernatant phase of the saliva.

- b. Taking care not to disturb the pellet and keeping the pellet as is in the original tubes, label the original tubes as “pellet”.
- ix. Freeze the samples at -80°C .

4.5 Processing of cervical cells

In a Pap smear test, a sample of cells is taken from the uterine cervix using a wooden spatula or a brush, smeared onto a slide, and examined under a microscope for abnormal cells (precancer or cancer). This protocol is a selected protocol from diverse collection procedures.

Note the following:

- i. It is best not to take a smear from a woman who is actively menstruating or has symptoms of an acute infection. Slight bleeding is acceptable.
- ii. Pregnancy is not an ideal time for a Pap smear, because it can give misleading results.

4.5.1 Taking the sample of cells

Insert the long tip of the spatula into the cervical os, and rotate the spatula through a full circle (360°). If the cervical broom brush is used, place the tip of the brush into the cervical os, and rotate the brush gently through three 360° circles.

4.5.2 Taking the Pap smear

- i. Smear both sides of the spatula (or the contents of the brush) onto the glass slide with one or two careful swipes. If any abnormalities are seen outside the area

sampled, take a separate specimen and smear it onto another slide.

- ii. Immediately fix each slide. Either use spray fixative, at a right angle to, and at a distance of 20 cm from, the slide, or immerse the slide in a container of 95% ethanol for at least 5 minutes. If the slide is not fixed immediately, the cells will dry and become misshapen; it will then not be possible to read the slide accurately in the laboratory.
- iii. Gently close and remove the speculum.
- iv. Place all used instruments in decontamination solution.

4.5.3 After taking the smear

- i. Label the frosted edge of each slide carefully.
- ii. On the patient record, note and illustrate any features you have noted: visibility of the transformation zone, inflammation, ulcers or other lesions, or abnormal discharge. Note whether other samples were taken, for example Pap smears of other areas, and if the woman has been referred elsewhere, note to whom and when.

4.6 Processing of hair and nails

These protocols are recommended for collecting hair or nail specimens.

4.6.1 Hair

Head hair may be collected as follows.

- i. Along an imaginary line drawn across the middle of the back of

the head from the centre of one ear to the centre of the other, gather a lock of hair at least the thickness of a pencil, and tie it together near the root end (near the scalp) using a small string or a rubber band.

- ii. Cut the hair as close to the scalp as possible without cutting the scalp.
- iii. Maintain the horizontal position of the hairs in the bundle by wrapping the cut section in aluminium foil or plastic wrap.
- iv. Indicate the root end and the tip end by marking the foil or plastic wrap with a permanent marker or with a paper label. **Do not use tape on the hair itself.**
- v. Place the specimen in a clean, dry, labelled paper envelope for shipment to the laboratory. Note whether bleaches, hair dye, or medications (e.g. selenium or minoxidil) were used.

Please note that hair from other sources (pubic, axillary, beard, moustache, chest, etc.) may also be analysed if head hair is not available.

4.6.2 Nails

A clean pair of nail clippers should be used. To clean nail clippers thoroughly, they should be rubbed with alcohol swabs. Nails should be clean of all polish, dirt, and debris. Nail clippings from each finger or toe should be collected and packaged separately in plastic bottles. Each bottle should be labelled with the mass of the nail collected and its source (e.g. right index finger) (NMS Labs and ExperTox).

References

- ABN (2007). Biorepository protocols. Australasian Biospecimen Network. Available from: http://www.iss.it/binary/ribo/cont/ABN_SOPs_Review_Mar07_final.pdf.
- Aleksandrova K, Pischon T, Jenab M, Bueno-de-Mesquita HB, Fedirko V, Norat T, et al. (2014). Combined impact of healthy lifestyle factors on colorectal cancer: a large European cohort study. *BMC Med.* 12(1):168. <http://dx.doi.org/10.1186/s12916-014-0168-4> PMID:25319089
- ARMA (2016). Brunswick Material Transfer Agreement. Cambridge, UK: Association of Research Managers and Administrators. Available from: <https://www.mrc.ac.uk/documents/pdf/brunswick-material-transfer-agreement/>.
- Ayache S, Panelli M, Marincola FM, Stroncek DF (2006). Effects of storage time and exogenous protease inhibitors on plasma protein levels. *Am J Clin Pathol.* 126(2):174–84. <http://dx.doi.org/10.1309/3WM7XJ7RD8BCLNKX> PMID:16891190
- BBMRI-ERIC (2016). BBMRI-ERIC Directory 2.0. Biobanking and BioMolecular resources Research Infrastructure–European Research Infrastructure Consortium. Available from: <http://bbmri-eric.eu/bbmri-eric-directory>.
- BCCM (2016). MOSAiCC Micro-organisms sustainable use and access regulation international code of conduct. Belgian Co-ordinated Collections of Micro-organisms. Available from: <http://bccm.belspo.be/projects/mosaicc>.
- Beauchamp TL, Childress JF (2013). Principles of biomedical ethics. 7th edition. Oxford University Press.
- Bergmann MM, Rehm J, Klipstein-Grobusch K, Boeing H, Schütze M, Drogan D, et al. (2013). The association of pattern of lifetime alcohol use and cause of death in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Int J Epidemiol.* 42(6):1772–90. <http://dx.doi.org/10.1093/ije/dyt154> PMID:24415611
- Betsou F, Gunter E, Clements J, DeSouza Y, Goddard KA, Guadagni F, et al. (2013). Identification of evidence-based biospecimen quality-control tools: a report of the International Society for Biological and Environmental Repositories (ISBER) Biospecimen Science Working Group. *J Mol Diagn.* 15(1):3–16. <http://dx.doi.org/10.1016/j.jmoldx.2012.06.008> PMID:23195791
- Bravo E, Calzolari A, De Castro P, Mabile L, Napolitani F, Rossi AM, et al. (2015). Developing a guideline to standardize the citation of biorepositories in journal articles (CoBRA). *BMC Med.* 13(1):33. <http://dx.doi.org/10.1186/s12916-015-0266-y> PMID:25855867
- Brochhausen M, Fransson MN, Kanaskar NV, Eriksson M, Merino-Martinez R, Hall RA, et al. (2013). Developing a semantically rich ontology for the biobank-administration domain. *J Biomed Semantics.* 4(1):23. <http://dx.doi.org/10.1186/2041-1480-4-23> PMID:24103726
- Burke W, Diekema DS (2006). Ethical issues arising from the participation of children in genetic research. *J Pediatr.* 149 (1 Suppl):S34–8. <http://dx.doi.org/10.1016/j.jpeds.2006.04.049> PMID:16829241
- Calam RR, Cooper MH (1982). Recommended “order of draw” for collecting blood specimens into additive-containing tubes. *Clin Chem.* 28(6):1399. PMID:7074955
- Cambon-Thomsen A, Thorisson GA, Mabile L; BRIF Workshop Group (2011). The role of a Biorepository Research Impact Factor as an incentive to share human biorepositories. *Nat Genet.* 43(6):503–4. <http://dx.doi.org/10.1038/ng.831> PMID:21614086
- CCB (2014). Biobank quality standard: collecting, storing and providing human biological material and data for research. London, UK: National Cancer Research Institute Confederation of Cancer Biobanks. Available from: <http://ccb.ncri.org.uk/wp-content/uploads/2014/03/Biobank-quality-standard-Version-1.pdf>.
- CEN (2015). European Committee for Standardization (CEN) norms. Available from: <https://standards.cen.eu/index.html>.
- Chaigneau C, Cabioch T, Beaumont K, Betsou F (2007). Serum biobank certification and the establishment of quality controls for biological fluids: examples of serum biomarker stability after temperature variation. *Clin Chem Lab Med.* 45(10):1390–5. <http://dx.doi.org/10.1515/CCLM.2007.160> PMID:17635068
- Chen H, Pang T (2015). A call for global governance of biobanks. *Bull World Health Organ.* 93(2):113–7. <http://dx.doi.org/10.2471/BLT.14.138420> PMID:25883404
- CIOMS (2002). International ethical guidelines for biomedical research involving human subjects. Geneva, Switzerland: Council for International Organizations of Medical Sciences and World Health Organization. Available from: www.cioms.ch/publications/layout_guide2002.pdf.

CLSI (2005). Collection, transport, preparation, and storage of specimens for molecular methods; approved guideline. CLSI document MM13-A, Vol. 25, No. 31. Wayne (PA), USA: Clinical and Laboratory Standards Institute. Available from: <http://shop.clsi.org/molecular-methods-documents/MM13.html>.

CLSI (2007). Procedures for the collection of diagnostic blood specimens by venipuncture; approved standard – sixth edition. CLSI document GP41-A6, Vol. 27, No. 26. Wayne (PA), USA: Clinical and Laboratory Standards Institute. Available from: http://shop.clsi.org/c.1253739/site/Sample_pdf/GP41A6_sample.pdf.

Council of Europe (2006). Recommendation Rec(2006)4 of the Committee of Ministers to member states on research on biological materials of human origin. Available from: <https://wcd.coe.int/ViewDoc.jsp?id=977859&BackColorInternet=9999CC&BackColorIntranet=FFBB55&BackColorLogged=FFAC75>.

Crowe FL, Key TJ, Appleby PN, Overvad K, Schmidt EB, Egeberg R, et al. (2012). Dietary fibre intake and ischaemic heart disease mortality: the European Prospective Investigation into Cancer and Nutrition-Heart study. *Eur J Clin Nutr*. 66(8):950–6. <http://dx.doi.org/10.1038/ejcn.2012.51> PMID:22617277

Cryo Bio System (2013). Fundamentals of cryobiology. Available from: http://www.cryobiosystem-imv.com/media/fundamentals_of_cryobiology_037984100_1259_18112013.pdf.

Dash A, Maine IP, Varambally S, Shen R, Chinnaiyan AM, Rubin MA (2002). Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. *Am J Pathol*. 161(5):1743–8. [http://dx.doi.org/10.1016/S0002-9440\(10\)64451-3](http://dx.doi.org/10.1016/S0002-9440(10)64451-3) PMID:12414521

De Cecco L, Musella V, Veneroni S, Cappelletti V, Bongarzone I, Callari M, et al. (2009). Impact of biospecimens handling on biomarker research in breast cancer. *BMC Cancer*. 9(1):409. <http://dx.doi.org/10.1186/1471-2407-9-409> PMID:19930681

De Jongh R, Vranken J, Vundelinckx G, Bosmans E, Maes M, Heylen R (1997). The effects of anticoagulation and processing on assays of IL-6, sIL-6R, sIL-2R and soluble transferrin receptor. *Cytokine*. 9(9):696–701. <http://dx.doi.org/10.1006/cyto.1997.0217> PMID:9325019

DGI (2016). The 9 classes of dangerous goods. Dangerous Goods International. Available from: <http://www.dgiglobal.com/classes>.

Eiseman E, Bloom G, Brower J, Clancy N, Olmsted SS (2003). Case studies of existing human tissue repositories: “best practices” for a biospecimen resource for the genomic and proteomic era. Santa Monica (CA), USA: RAND Corporation. Available from: http://www.rand.org/pubs/monographs/2004/RAND_MG120.pdf.

ESMO (2010). Improving rare cancer care in Europe – recommendations on stakeholder actions and public policies. European Society for Medical Oncology. Available from: http://www.rarecancerseurope.org/content/download/16802/296577/file/ESMO_Rare_Cancers_recommendations_2010.pdf.

European Commission (2012a). Biobanks for Europe: a challenge for governance. Directorate-General for Research and Innovation. Brussels, Belgium: European Commission. Available from: https://ec.europa.eu/research/swafs/pdf/pub_archive/biobanks-for-europe_en.pdf.

European Commission (1995). Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data. Official Journal L 281/31–50. Available from: <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31995L0046:en:HTML>.

European Commission (2012b). Proposal for a Regulation of the European Parliament and of the Council on the protection of individuals with regard to the processing of personal data and on the free movement of such data (General Data Protection Regulation). Brussels, Belgium: European Commission. Available from: <http://eur-lex.europa.eu/legal-content/EN/ALL/?uri=celex%3A52012PC0011>

European Commission (2016). Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). Official Journal L 119/1–88. Available from: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2016.119.01.0001.01.ENG.

European Society of Radiology (2015). ESR position paper on imaging biobanks. *Insights Imaging*. 6(4):403–10. <http://dx.doi.org/10.1007/s13244-015-0409-x> PMID:25999018

Furuta K, Schacter B (2015). Report on status of ISO276/WG2 on biobanks and bioresources: international standards for biobanking. *Biopreserv Biobank*. 13(6):452–3. <http://dx.doi.org/10.1089/bio.2015.29041.kf> PMID:26697915

GA4GH (2016). Global Alliance for Genomics and Health: about the Global Alliance. Available from: <http://genomicsandhealth.org/about-global-alliance>.

GA4GH (2015a). Global Alliance for Genomics and Health: consent policy. Available from: <https://genomicsandhealth.org/files/public/Consent%20Policy%20%28Final%20-%2027%20May%202015%29.pdf>.

GA4GH (2015b). Global Alliance for Genomics and Health: privacy and security policy. Available from: [https://genomicsandhealth.org/files/public/Privacy%20and%20Security%20Policy%20\(Final%20-%2026%20May%202015\).pdf](https://genomicsandhealth.org/files/public/Privacy%20and%20Security%20Policy%20(Final%20-%2026%20May%202015).pdf).

- García-Closas M, Egan KM, Abruzzo J, Newcomb PA, Titus-Ernstoff L, Franklin T, et al. (2001). Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash. *Cancer Epidemiol Biomarkers Prev.* 10(6):687–96. PMID:11401920
- Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, et al.; American College of Medical Genetics and Genomics (2013). ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. *Genet Med.* 15(7):565–74. <http://dx.doi.org/10.1038/gim.2013.73> PMID:23788249
- Griese M (1999). Pulmonary surfactant in health and human lung diseases: state of the art. *Eur Respir J.* 13(6):1455–76. <http://dx.doi.org/10.1183/09031936.99.13614779> PMID:10445627
- Gündisch S, Slotta-Huspenina J, Verderio P, Ciniselli CM, Pizzamiglio S, Schott C, et al. (2014). Evaluation of colon cancer histomorphology: a comparison between formalin and PAXgene tissue fixation by an international ring trial. *Virchows Arch.* 465(5):509–19. <http://dx.doi.org/10.1007/s00428-014-1624-4> PMID:25085759
- H3Africa (2013). H3Africa guidelines for community engagement. Developed by the H3Africa Working Group on Ethics and Regulatory Issues for the Human Heredity and Health (H3Africa) Consortium. Available from: http://www.h3africa.org/images/GuidelinesPolicyDocs/CE%20Guidelines_Final.pdf.
- Hainaut P, Caboux E, Bevilacqua G, Bosman F, Dassel T, Hoefler H, et al. (2009). Pathology as the cornerstone of human tissue banking: European consensus expert group report. *Biopreserv Biobank.* 7(3):157–60. <http://dx.doi.org/10.1089/bio.2010.7303> PMID:24835883
- Hall JA, Daidone MG, Peters GJ, Harbeck N, Lacombe D, Sleijfer S (2011). Integrating collection of biospecimens in clinical trials: the approach of the European Organization for Research and Treatment of Cancer. *Biopreserv Biobank.* 9(2):181–6. <http://dx.doi.org/10.1089/bio.2011.0003> PMID:24846265
- Harris JR, Burton P, Knoppers BM, Lindpaintner K, Bledsoe M, Brookes AJ, et al. (2012). Toward a roadmap in global biobanking for health. *Eur J Hum Genet.* 20(11):1105–11. <http://dx.doi.org/10.1038/ejhg.2012.96> PMID:22713808
- Heins M, Heil W, Withold W (1995). Storage of serum or whole blood samples? Effects of time and temperature on 22 serum analytes. *Eur J Clin Chem Clin Biochem.* 33(4):231–8. PMID:7626695
- Hens K, Lévesque E, Dierickx K (2011). Children and biobanks: a review of the ethical and legal discussion. *Hum Genet.* 130(3):403–13. <http://dx.doi.org/10.1007/s00439-011-1031-8> PMID:21660506
- Hu S, Loo JA, Wong DT (2007). Human saliva proteome analysis. *Ann N Y Acad Sci.* 1098(1):323–9. <http://dx.doi.org/10.1196/annals.1384.015> PMID:17435138
- Hubel A, Spindler R, Skubitz AP (2014). Storage of human biospecimens: selection of the optimal storage temperature. *Biopreserv Biobank.* 12(3):165–75. <http://dx.doi.org/10.1089/bio.2013.0084> PMID:24918763
- HUPO (2015). Human Proteome Organization: about HUPO. Available from: <https://www.hupo.org/about-hupo/>.
- IATA (2015a). Dangerous Goods Regulations (DGR). Montreal, Canada: International Air Transport Association. Available from: <http://www.iata.org/publications/dgr/Pages/index.aspx>.
- IATA (2015b). IATA classification: Division 6.2 – Infectious substances. Montreal, Canada: International Air Transport Association. Available from: <https://www.iata.org/whatwedo/cargo/dgr/Documents/infectious-substance-classification-DGR56-en.pdf>.
- IATA (2015c). Packing instructions – Class 6 – Toxic and infectious substances. Montreal, Canada: International Air Transport Association. Available from: <https://www.iata.org/whatwedo/cargo/dgr/Documents/packing-instruction-650-DGR56-en.pdf>.
- ICAO (1986). Technical instructions for the safe transport of dangerous goods by air. Montreal, Canada: International Civil Aviation Organization. Available from: <http://www.icao.int/safety/DangerousGoods/Pages/technical-instructions.aspx>.
- ISBER (2012). 2012 Best practices for repositories: collection, storage, retrieval, and distribution of biological materials for research. International Society for Biological and Environmental Repositories. *Biopreserv Biobank.* 10(2):79–161. <http://dx.doi.org/10.1089/bio.2012.1022> PMID:24844904
- ISO (2012). ISO 15189:2012. Medical laboratories – Requirements for quality and competence. Geneva, Switzerland: International Organization for Standardization. Available from: http://www.iso.org/iso/catalogue_detail?csnumber=56115.
- Kaye J, Hawkins N (2014). Data sharing policy design for consortia: challenges for sustainability. *Genome Med.* 6(1):4. <http://dx.doi.org/10.1186/gm523> PMID:24475754
- Kersting M, Prokein J, Bernemann I, Drobek D, Illig T (2015). IT systems for biobanking: a brief overview. Hannover, Germany: Hannover United Biobank, Hannover Medical School. Available from: http://www.markus-kersting.de/wp-content/uploads/2014/12/Poster_Biobank_Systeme_HUB_2014_12_01_mk_b.pdf.
- King IB, Satia-Abouta J, Thornquist MD, Bigler J, Patterson RE, Kristal AR, et al. (2002). Buccal cell DNA yield, quality, and collection costs: comparison of methods for large-scale studies. *Cancer Epidemiol Biomarkers Prev.* 11(10 Pt 1):1130–3. PMID:12376522
- Knoppers BM, Chisholm RL, Kaye J, Cox D, Thorogood A, Burton P, et al.; P3G International Steering Committee (2013). A P3G generic access agreement for population genomic studies. *Nat Biotechnol.* 31(5):384–5. <http://dx.doi.org/10.1038/nbt.2567> PMID:23657386

- Kon OL (2001). Tissue banking for biomedical research. Commissioned paper for the Human Genetics Subcommittee of the Bioethics Advisory Committee. National Cancer Centre Singapore. Available from: <http://www.bioethics-singapore.org/images/uploadfile/52533%20PMHT%20AppendixB-Dr%20Kon.pdf>.
- Kosseim P, Dove ES, Baggaley C, Meslin EM, Cate FH, Kaye J, et al. (2014). Building a data sharing model for global genomic research. *Genome Biol.* 15(8):430. <http://dx.doi.org/10.1186/s13059-014-0430-2> PMID:25221857
- Kumari S, Ichhpujani RL (2000). Guidelines on standard operating procedures for microbiology. New Delhi, India: World Health Organization Regional Office for South-East Asia. Available from: http://apps.searo.who.int/PDS_DOCS/B0217.pdf.
- Laurie G (2011). Reflexive governance in biobanking: on the value of policy led approaches and the need to recognise the limits of law. *Hum Genet.* 130(3):347–56. <http://dx.doi.org/10.1007/s00439-011-1066-x> PMID:21766192
- Lehmann S, Guadagni F, Moore H, Ashton G, Barnes M, Benson E, et al. (2012). Standard preanalytical coding for biospecimens: review and implementation of the Sample PREanalytical Code (SPREC). *Biopreserv Biobank.* 10(4):366–74. <http://dx.doi.org/10.1089/bio.2012.0012> PMID:24849886
- Lengellé J, Panopoulos E, Betsou F (2008). Soluble CD40 ligand as a biomarker for storage-related preanalytic variations of human serum. *Cytokine.* 44(2):275–82. <http://dx.doi.org/10.1016/j.cyt.2008.08.010> PMID:18851919
- Lin DW, Coleman IM, Hawley S, Huang CY, Dumpit R, Gifford D, et al. (2006). Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. *J Clin Oncol.* 24(23):3763–70. <http://dx.doi.org/10.1200/JCO.2005.05.1458> PMID:16822846
- Mager SR, Oomen MH, Morente MM, Ratcliffe C, Knox K, Kerr DJ, et al. (2007). Standard operating procedure for the collection of fresh frozen tissue samples. *Eur J Cancer.* 43(5):828–34. <http://dx.doi.org/10.1016/j.ejca.2007.01.002> PMID:17329097
- Makowski GS, Davis EL, Hopfer SM (1996). The effect of storage on Guthrie cards: implications for deoxyribonucleic acid amplification. *Ann Clin Lab Sci.* 26(5):458–69. PMID:8879364
- Malentacchi F, Pizzamiglio S, Verderio P, Pazzagli M, Orlando C, Ciniselli CM, et al. (2015). Influence of storage conditions and extraction methods on the quantity and quality of circulating cell-free DNA (ccfDNA): the SPIDIA-DNAplax External Quality Assessment experience. *Clin Chem Lab Med.* 53(12):1935–42. <http://dx.doi.org/10.1515/ccim-2014-1161> PMID:25883202
- Mallette, A., Tassé AM, Knoppers BM (2013). P3G model framework for biobank governance. Public Population Project in Genomics and Society. Available from: http://www.p3g.org/system/files/biobank_toolkit_documents/P3G%20Model%20Framework%20for%20Biobank%20Governance%20FINAL%20%281%29_0.pdf.
- Matharoo-Ball B, Thomson BJ (2014). Nottingham Health Science Biobank: a sustainable bioresource. *Biopreserv Biobank.* 12(5):312–6. <http://dx.doi.org/10.1089/bio.2014.0056> PMID:25340939
- Mayrhofer MT, Holub P, Wutte A, Litton JE (2016). BBMRI-ERIC: the novel gateway to biobanks: from humans to humans. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitschutz.* 59(3):379–84. <http://dx.doi.org/10.1007/s00103-015-2301-8> PMID:26860601
- Medical Research Council and Wellcome Trust (2014). Framework on the feedback of health-related findings in research. Available from: <https://www.mrc.ac.uk/documents/pdf/mrc-wellcome-trust-framework-on-the-feedback-of-health-related-findings-in-researchpdf>.
- Mendy M, Kirk GD, van der Sande M, Jeng-Barry A, Lesi OA, Hainaut P, et al. (2005). Hepatitis B surface antigenaemia and alpha-foetoprotein detection from dried blood spots: applications to field-based studies and to clinical care in hepatitis B virus endemic areas. *J Viral Hepat.* 12(6):642–7. <http://dx.doi.org/10.1111/j.1365-2893.2005.00641.x> PMID:16255766
- Mendy M, Lawlor R, Van Keppel AL, Riegman P, Betsou F, Cohen O (2013). Biosampling and biobanking. In: Rebbeck TR, editor. Handbook for cancer research in Africa. Brazzaville, Republic of the Congo: World Health Organization Regional Office for Africa; pp 77–94. Available from: <http://apps.who.int/iris/bitstream/10665/100065/1/9789290232216.pdf>.
- Miller JM, Astles R, Baszler T, Chapin K, Carey R, Garcia L, et al.; Biosafety Blue Ribbon Panel; Centers for Disease Control and Prevention (CDC) (2012). Guidelines for safe work practices in human and animal medical diagnostic laboratories. Recommendations of a CDC-convened, Biosafety Blue Ribbon Panel. *MMWR Suppl.* 61(1):1–102. PMID:22217667
- Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, et al. (2011). Biospecimen reporting for improved study quality (BRISQ). *Cancer Cytopathol.* 119(2):92–101. <http://dx.doi.org/10.1002/cncy.20147> PMID:21433001
- Morente MM, Mager R, Alonso S, Pezzella F, Spatz A, Knox K, et al. (2006). TuBaFrost 2: standardising tissue collection and quality control procedures for a European virtual frozen tissue bank network. *Eur J Cancer.* 42(16):2684–91. <http://dx.doi.org/10.1016/j.ejca.2006.04.029> PMID:17027255
- MRC (2014). Human tissue and biological samples for use in research: operational and ethical guidelines. United Kingdom Medical Research Council. Available from: <http://www.mrc.ac.uk/publications/browse/human-tissue-and-biological-samples-for-use-in-research/>.

- Mulot C, Stücker I, Clavel J, Beaune P, Lorient MA (2005). Collection of human genomic DNA from buccal cells for genetics studies: comparison between cytobrush, mouthwash, and treated card. *J Biomed Biotechnol.* 2005(3):291–6. <http://dx.doi.org/10.1155/JBB.2005.291> PMID:16192688
- NCI (2011). Informed consent template for cancer treatment trials. United States National Cancer Institute. Available from: <https://www.rtog.org/LinkClick.aspx?fileticket=H5dVynC5MVA%3D&tabid=347>.
- NCI (2016). NCI best practices for biospecimen resources. Biorepositories and Biospecimen Research Branch, United States National Cancer Institute. Available from: <http://biospecimens.cancer.gov/bestpractices/2016-NCIBestPractices.pdf>.
- NCRI (2009). Samples and data for research: template for access policy development. London, UK: National Cancer Research Institute. Available from: <http://www.ncri.org.uk/wp-content/uploads/2013/09/Initiatives-Biobanking-2-Access-template.pdf>.
- Norlin L, Fransson MN, Eriksson M, Merino-Martinez R, Anderberg M, Kurtovic S, et al. (2012). A minimum data set for sharing biobank samples, information, and data: MIABIS. *Biopreserv Biobank.* 10(4):343–8. <http://dx.doi.org/10.1089/bio.2012.0003> PMID:24849882
- Nuffield Council on Bioethics (2002). The ethics of research related to healthcare in developing countries. Available from: <http://nuffieldbioethics.org/wp-content/uploads/2014/07/Ethics-of-research-related-to-healthcare-in-developing-countries-1.pdf>.
- Ockè MC, Schrijver J, Obermann-de Boer GL, Bloemberg BP, Haenen GR, Kromhout D (1995). Stability of blood (pro)vitamins during four years of storage at -20 degrees C: consequences for epidemiologic research. *J Clin Epidemiol.* 48(8):1077–85. [http://dx.doi.org/10.1016/0895-4356\(94\)00232-F](http://dx.doi.org/10.1016/0895-4356(94)00232-F) PMID:7775995
- OECD (2001). Biological resource centres: underpinning the future of life sciences and biotechnology. Paris, France: Organisation for Economic Co-operation and Development. Available from: <https://www.oecd.org/sti/bio/tech/2487422.pdf>.
- OECD (2007). OECD best practice guidelines for biological resource centres. Paris, France: Organisation for Economic Co-operation and Development. Available from: <http://www.oecd.org/sti/biotech/38777417.pdf>.
- OECD (2009). OECD guidelines on human biobanks and genetic research databases. Paris, France: Organisation for Economic Co-operation and Development. Available from: <https://www.oecd.org/sti/biotech/44054609.pdf>.
- P3G (2016). Public Population Project in Genomics and Society: about P3G. Available from: <http://www.p3g.org/about-p3g>.
- Pilch B, Mann M (2006). Large-scale and high-confidence proteomic analysis of human seminal plasma. *Genome Biol.* 7(5):R40. <http://dx.doi.org/10.1186/gb-2006-7-5-r40> PMID:16709260
- Precision Medicine Initiative Working Group (2015). The Precision Medicine Initiative Cohort Program – building a research foundation for 21st century medicine. Precision Medicine Initiative (PMI) Working Group Report to the Advisory Committee to the Director, NIH. United States National Institutes of Health. Available from: <https://www.nih.gov/sites/default/files/research-training/initiatives/pmi/pmi-working-group-report-20150917-2.pdf>.
- RCR (2011). Management of incidental findings detected during research imaging. London, UK: The Royal College of Radiologists. Available from: https://www.rcr.ac.uk/sites/default/files/publication/BFCR%2811%298_ethics.pdf.
- Reynolds HY (2000). Use of bronchoalveolar lavage in humans – past necessity and future imperative. *Lung.* 178(5):271–93. <http://dx.doi.org/10.1007/s004080000032> PMID:11147312
- Riegman PH, Dinjens WN, Oomen MH, Spatz A, Ratcliffe C, Knox K, et al. (2006a). TuBaFrost 1: uniting local frozen tumour banks into a European network: an overview. *Eur J Cancer.* 42(16):2678–83. <http://dx.doi.org/10.1016/j.ejca.2006.04.031> PMID:17027254
- Riegman PH, Oomen MH, Dinjens WN, Oosterhuis JW, Lam KH, Spatz A, et al. (2006b). TuBaFrost: European virtual tumor tissue banking. *Adv Exp Med Biol.* 587:65–74. http://dx.doi.org/10.1007/978-1-4020-5133-3_6 PMID:17163156
- Rohrmann S, Linseisen J, Nöthlings U, Overvad K, Egeberg R, Tjønneland A, et al. (2013). Meat and fish consumption and risk of pancreatic cancer: results from the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer.* 132(3):617–24. <http://dx.doi.org/10.1002/ijc.27637> PMID:22610753
- Smith LM, Burgoyne LA (2004). Collecting, archiving and processing DNA from wildlife samples using FTA databasing paper. *BMC Ecol.* 4(1):4. <http://dx.doi.org/10.1186/1472-6785-4-4> PMID:15072582
- Steinberg K, Beck J, Nickerson D, Garcia-Closas M, Gallagher M, Caggana M, et al. (2002). DNA banking for epidemiologic studies: a review of current practices. *Epidemiology.* 13(3):246–54. <http://dx.doi.org/10.1097/00001648-200205000-00003> PMID:11964924
- Tassé AM (2011). The return of results of deceased research participants. *J Law Med Ethics.* 39(4):621–30. <http://dx.doi.org/10.1111/j.1748-720X.2011.00629.x> PMID:22084848
- Thorogood A, Joly Y, Knoppers BM, Nilsson T, Metrakos P, Lazaris A, et al. (2014). An implementation framework for the feedback of individual research results and incidental findings in research. *BMC Med Ethics.* 15:88. <http://dx.doi.org/10.1186/1472-6939-15-88> PMID:25539799

- UK Biobank Ethics and Governance Council (2016). Ethics and governance framework. Available from: <http://egcukbiobank.org.uk/Ethics-and-governance-framework>.
- UK Biobank Ethics and Governance Council (2015). Feedback of health related findings: foreground principles and background perspectives. London, UK: Wellcome Trust. Available from: http://egcukbiobank.org.uk/sites/default/files/UKBEGC_FeedbackReport.pdf.
- UK Biobank Ethics and Governance Council (2009). Workshop report: involving publics in biobank research and governance. London, UK: Wellcome Trust. Available from: <http://egcukbiobank.org.uk/sites/default/files/meetings/EGC%20workshop%20report.pdf>.
- UNECE (2015). United Nations recommendations on the transport of dangerous goods – model regulations, 19th revised edition. United Nations Economic Commission for Europe. Available from: http://www.unece.org/trans/danger/publi/unrec/rev19/19files_e.html.
- van Ommen GJ, Törnwall O, Bréchet C, Dagher G, Galli J, Hveem K, et al. (2015). BBMRI-ERIC as a resource for pharmaceutical and life science industries: the development of biobank-based Expert Centres. *Eur J Hum Genet.* 23(7):893–900. <http://dx.doi.org/10.1038/ejhg.2014.235> PMID:25407005
- Vaught J, Kelly A, Hewitt R (2009). A review of international biobanks and networks: success factors and key benchmarks. *Biopreserv Biobank.* 7(3):143–50. <http://dx.doi.org/10.1089/bio.2010.0003> PMID:24835880
- Vaught J, Rogers J, Carolin T, Compton C (2011). Biobankonomics: developing a sustainable business model approach for the formation of a human tissue biobank. *J Natl Cancer Inst Monogr.* 2011(42):24–31. <http://dx.doi.org/10.1093/jncimonographs/lgr009> PMID:21672892
- Viertler C, Groelz D, Gündisch S, Kashofer K, Reischauer B, Riegman PH, et al. (2012). A new technology for stabilization of biomolecules in tissues for combined histological and molecular analyses. *J Mol Diagn.* 14(5):458–66. <http://dx.doi.org/10.1016/j.jmoldx.2012.05.002> PMID:22749745
- Voegelé C, Alteyrac L, Caboux E, Smans M, Lesueur F, Le Calvez-Kelm F, et al. (2010). A sample storage management system for biobanks. *Bioinformatics.* 26(21):2798–800. <http://dx.doi.org/10.1093/bioinformatics/btq502> PMID:20807837
- Voegelé C, Bouchereau B, Robinot N, McKay J, Damiécki P, Alteyrac L (2013). A universal open-source Electronic Laboratory Notebook. *Bioinformatics.* 29(13):1710–2. <http://dx.doi.org/10.1093/bioinformatics/btt253> PMID:23645817
- Wallace SE, Gourné EG, Laurie G, Shoush O, Wright J (2016). Respecting autonomy over time: policy and empirical evidence on re-consent in longitudinal biomedical research. *Bioethics.* 30(3):210–7. <http://dx.doi.org/10.1111/bioe.12165> PMID:25960157
- WHO (2006). Biorisk management: laboratory biosecurity guidance. Geneva, Switzerland: World Health Organization. Available from: www.who.int/csr/resources/publications/bio_safety/WHO_CDS_EPR_2006_6.pdf.
- WHO (2005). Guidance on regulations for the transport of infectious substances. Geneva, Switzerland: World Health Organization. Available from: http://www.who.int/csr/resources/publications/biosafety/WHO_CDS_CSR_LYO_2005_22r%20.pdf.
- WHO (2012). Guidance on regulations for the transport of infectious substances 2013–2014. Applicable as from 1 January 2013. Geneva, Switzerland: World Health Organization. Available from: http://apps.who.int/iris/bitstream/10665/78075/1/WHO_HSE_GCR_2012.12_eng.pdf.
- WHO (2015). Guidance on regulations for the transport of infectious substances 2015–2016. Applicable as from 1 January 2015. Geneva, Switzerland: World Health Organization. Available from: http://apps.who.int/iris/bitstream/10665/149288/1/WHO_HSE_GCR_2015.2_eng.pdf.
- WMA (2013). WMA Declaration of Helsinki – Ethical principles for medical research involving human subjects. World Medical Association. Available from: <https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>
- WMA (2016). WMA Declaration of Taipei on ethical considerations regarding health databases and biobanks. World Medication Association. Available from: <http://www.wma.net/en/30publications/10policies/d1/>.
- Yokota M, Tatsumi N, Nathalang O, Yamada T, Tsuda I (1999). Effects of heparin on polymerase chain reaction for blood white cells. *J Clin Lab Anal.* 13(3):133–40. [http://dx.doi.org/10.1002/\(SICI\)1098-2825\(1999\)13:3<133::AID-JCLA8>3.0.CO;2-Q](http://dx.doi.org/10.1002/(SICI)1098-2825(1999)13:3<133::AID-JCLA8>3.0.CO;2-Q) PMID:10323479
- Yuille M, van Ommen GJ, Bréchet C, Cambon-Thomsen A, Dagher G, Landegren U, et al. (2008). Biobanking for Europe. *Brief Bioinform.* 9(1):14–24. <http://dx.doi.org/10.1093/bib/bbm050> PMID:17959611

Disclosures of interests

Dr Joakim Dillner reports that his unit at the Karolinska Institutet benefited from research funding from Sanofi Pasteur MSD and from Merck in 2014.

Dr Jan-Eric Litton reports holding intellectual property rights to the biobank lexicon Minimum Information about Biobank Data Sharing (MIABIS).

Dr Kurt Zatloukal reports having received personal consultancy fees from AstraZeneca and Daiichi Sankyo, support for travel from GlaxoSmithKline, and support from Daiichi Sankyo, Qiagen, and Siemens as an R&D partner. Dr Zatloukal is a European Committee for Standardization (CEN)/International Organization for Standardization (ISO) Technical Committee member.



© R. Dray/IARC

ISBN 978-92-832-2464-8